Abstract:Putu Yuliandari, 1 I Putu Bayu Mayura 2 1 Centre for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Centre, Bogor, West Java, Indonesia; 2 Department of Microbiology, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia Correspondence: Putu Yuliandari, National Research and Innovation Agency (BRIN), Cibinong Science Centre, Jl. Raya Jakarta - Bogor Km. 46, Cibinong, Bogor, West Java, Indonesia, Email View the original paper by Dr Xiao and colleagues We have read the article by Xiao et al about "Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients". 1 This study investigates the impact of Helicobacter pylori infection on glucose metabolism, lipid metabolism, and inflammatory cytokines in patients with nonalcoholic fatty liver disease (MASLD). Nonalcoholic fatty liver disease, now known as metabolic-dysfunction-associated steatotic liver disease (MASLD), is a leading cause of chronic liver disease worldwide. The global prevalence of MASLD has been increasing over time, with a recent meta-analysis estimating that MASLD afflicts 32% of the adult population. 2 Since the initial report of H. pylori DNA being detected in the liver of non alcoholic fatty liver disease patients, numerous studies have investigated the relationship between H. pylori infection and this disease. 3 The authors have utilized diagnostic criteria from the "Prevention and Treatment Guidelines for Nonalcoholic Fatty Liver Disease" which may not be readily accessible to an international audience due to the language barrier. The retrospective nature of the study implies reliance on diagnostic standards that have since been updated, as noted in the June 2023 revision by Rinella et al. 4 The study's methodology, particularly the use of the 14C-urea breath test to diagnose H. pylori infection, has inherent limitations. Future investigations could enhance diagnostic accuracy through molecular techniques, such as PCR, to detect H. pylori and its virulence factors, including variations in the cytotoxin-associated gene A (Cag A) status. 3 There is a direct association between H. pylori infection and insulin resistance and dyslipidemia, both presently recognized as factors contributing to the development of MASLD. Several studies revealed a positive correlation between H. pylori infection and MASLD, similar to this study, while some clinical studies negate this conclusion. 3 This may be due to variability in H. pylori strains, inconsistent H. pylori diagnostic methods, updated MASLD diagnostic criteria, and regional differences in race, genetics, lifestyle, and dietary habits. A possible mechanism of interaction between H. pylori infection and MASLD involves fetuin-A or alpha 2-HS glycoprotein (AHSG). Higher serum fetuin-A levels in H. pylori-positive patients have been reported to correlate with impaired insulin sensitivity and glucose tolerance. 5 Fetuin-A also acts as an endogenous adaptor protein for free fatty acid-mediated activation of TLR4 in mice. This might reflect the presence of a broad panel of inflammatory mediators (c-reactive protein, TNF-α, IL-6, IL-1β) in patients suffering from H. pylori infection. 6 Future research should employ large-scale and multi-center randomized controlled trials to objectively and effectively assess the influence of H. pylori infection in MASLD patients. We acknowledge and appreciate this study's contribution to the field of hepatology and gastroenterology, highlighting the extragastric influence of H. pylori on metabolic diseases. It lays a foundation for future research to explore the relationships between H. pylori infection, metabolic dysregulation, and MASLD more deeply, potentially leading to improved patient outcomes. The authors would like to acknowledge all the researchers and Prof. Dr. Sunarno in the Center for Biomedical Research BRIN for their continuous support. The authors would also like to convey gratitude to the research team of Xiao et al for their valuable research report. The authors have disclosed no conflicts of interest in this communication. 1. Xiao Q, Wang R, Wu H, Kuang W, Meng W, Cheng Z. Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients. J Multidisciplinary Healthcare . 2024;17:1127–1135. doi:10.2147/JMDH.S453429 2. Teng MLP, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol . 2023;29(supp1):32–42. doi:10.3350/CMH.2022.036 -Abstract Truncated-

The interplay between Helicobacter pylori infection and rs738409 PNPLA3 in metabolic dysfunction-associated steatotic liver disease

Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease

Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis.

Relationship between Helicobacter pylori infection and risk of metabolic dysfunction‐associated steatotic liver disease: An updated meta‐analysis

Epidemiological Study on the Interaction between the PNPLA3 (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease

Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD

Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD

Association between Helicobacter pylori infection, MASLD, and liver fibrosis in patients with severe obesity: a single-center experience

Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

O-12 HELICOBACTER PYLORI VIRULENCE GENES ARE ASSOCIATED WITH NAFLD SEVERITY: A CROSS SECTIONAL STUDY IN DYSPEPTIC PATIENTS

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD

Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients

Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population

Integrated analysis of the transcriptome and its interaction with the metabolome in metabolic associated fatty liver disease: Gut microbiome signatures, correlation networks, and effect of PNPLA3 genotype

Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants

Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease

Response to Article "Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients"